Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Incyte (INCY) and Zimmer Biomet Holdings (ZBH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neuronetics (STIM – Research Report), Incyte (INCY – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neuronetics (STIM)
Canaccord Genuity analyst William Plovanic maintained a Buy rating on Neuronetics yesterday and set a price target of $7.00. The company’s shares closed last Tuesday at $1.46.
According to TipRanks.com, Plovanic is a 3-star analyst with an average return of
Currently, the analyst consensus on Neuronetics is a Moderate Buy with an average price target of $6.25, a 311.2% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $5.50 price target.
See the top stocks recommended by analysts >>
Incyte (INCY)
Goldman Sachs analyst Salveen Richter maintained a Hold rating on Incyte today and set a price target of $98.00. The company’s shares closed last Tuesday at $100.05.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $107.06 average price target, which is a 3.9% upside from current levels. In a report issued on January 29, RBC Capital also maintained a Hold rating on the stock with a $95.00 price target.
Zimmer Biomet Holdings (ZBH)
In a report released today, Joanne Wuensch from Citi maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $98.00. The company’s shares closed last Tuesday at $91.40.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
Zimmer Biomet Holdings has an analyst consensus of Hold, with a price target consensus of $100.93, a 7.2% upside from current levels. In a report released today, TipRanks – OpenAI also downgraded the stock to Hold with a $96.00 price target.
